scRNA-seq revealed that CD4+T cells have diverse functions, which are significantly associated with ICB therapy and have a positive impact on ICB prognosis; combination therapy can increase Th1-like CD4+ effector T cells. It was clarified that the 4PD-1hi CD4+ subpopulation is associated with high tumor mutation load. The gene discussed is CD4; the disease is neoplasm.